Comparing single vs double beam proton therapy for certain tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the toxicity and efficacy of proton therapy delivered using either one or two beams for patients with chordoma, chondrosarcoma, Ewing sarcoma, and osteosarcoma. The Proteus®One system allows for precise targeting of tumors with reduced adverse effects compared to traditional radiation methods. By assessing the differences in patient outcomes between the two approaches, the study aims to determine if a single beam can be as effective as the conventional two-beam method while minimizing treatment time and patient discomfort.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Chordoma, chondrosarcoma of the skull base and spine, Ewing's sarcoma, and osteosarcoma meeting the criteria for treatment by proton therapy
* Tumour requiring 2 beams
* MRI less than one month old
* PS 0-2.
* Patient who has read the patient information note and signed the consent form.
* Patient with healthcare insurance cover.
* Age over 18 years.
* For women of childbearing age, negative urine pregnancy test and effective contraception in place for the duration of treatment and for six months following the end of treatment.

Exclusion Criteria:

* Persons deprived of their liberty or under guardianship.
* Unable to undergo the medical follow-up of the clinical investigation for geographical, social or psychological reasons.
* Patient eligible for symptom reduction surgery Vulnerable populations and participants defined in Articles 64 to 68 of Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017.

Where it's running

• Centre Antoine lacassagne
  Nice, France Recruiting

Study contacts

• Study coordinator: Clement DEVIC, PhD
• Email: clement.devic@nice.unicancer.fr
• Phone: 0492031511

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Alpha/beta T‑Cell and B‑Cell Depletion plus Zoledronic Acid for Pediatric and Young Adult Solid Tumors

  This study will try removing alpha/beta T cells and B cells from donor stem cell grafts and giving zoledronic acid to see if it helps children and young adults (6 months to 25 years) with relapsed or high‑risk solid tumors tolerate allogeneic transplant and reduce relapse.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida · NCT06625190

• Personalized home exercise program for patients with bone tumors after surgery

  This study tests whether a personalized home exercise program helps patients with bone tumors recover better after surgery and chemotherapy.

  Recruiting Istituto Ortopedico Rizzoli · Bologna · NCT05779670

• Using Regorafenib to Maintain Treatment Benefits After Initial Therapy for Bone Sarcomas

  This study is testing if the drug regorafenib can help people with bone sarcomas stay cancer-free longer after their initial treatment.

  Recruiting at 12 sites Centre Leon Berard · Besançon and 15 other locations · NCT04055220

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• Adaptive Proton Therapy for Pediatric Solid Tumors and Hodgkin Lymphoma

  This study tests a regular imaging approach to see if proton therapy plans for children with solid tumors or Hodgkin lymphoma should be updated during treatment.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07514819

• Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

  This trial tests whether adding eflornithine (DFMO) as extra or maintenance therapy can improve survival for young people with Ewing sarcoma or osteosarcoma.

  Recruiting at 3 sites Phase 2 Milton S. Hershey Medical Center · Tampa, Florida and 2 other locations · NCT07321912

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.